IBP Stock Overview
Engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Indo-Bangla Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳10.60 |
| 52 Week High | ৳20.20 |
| 52 Week Low | ৳6.80 |
| Beta | 0.18 |
| 1 Month Change | 6.00% |
| 3 Month Change | 19.10% |
| 1 Year Change | -40.45% |
| 3 Year Change | -40.01% |
| 5 Year Change | -52.81% |
| Change since IPO | -69.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBP | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | 6.0% | 0.8% | 0.5% |
| 1Y | -40.4% | -28.8% | -18.1% |
Return vs Industry: IBP underperformed the BD Pharmaceuticals industry which returned -28.8% over the past year.
Return vs Market: IBP underperformed the BD Market which returned -18.1% over the past year.
Price Volatility
| IBP volatility | |
|---|---|
| IBP Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in BD Market | 6.6% |
| 10% least volatile stocks in BD Market | 2.4% |
Stable Share Price: IBP's share price has been volatile over the past 3 months compared to the BD market.
Volatility Over Time: IBP's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of BD stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 152 | A. F. M. Huq | www.indo-banglapharma.com |
Indo-Bangla Pharmaceuticals Limited engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. Its principal products include analgesics and antipyretics, anthelmintic, anti-asthmatic, gastroprokinetic and antiemetic, antiprotozoal, non-hormone sex stimulant, non-steroidal, anti-inflammatory, steroids, and vitamins and minerals, as well as respiratory, cardiovascular, central nervous system, dermatology, and gastrointestinal categories. The company markets its products in various forms, such as tablets, capsules, intravenous fluids, liquids, suppositories, and injectables.
Indo-Bangla Pharmaceuticals Limited Fundamentals Summary
| IBP fundamental statistics | |
|---|---|
| Market cap | ৳1.23b |
| Earnings (TTM) | -৳44.98m |
| Revenue (TTM) | ৳119.08m |
10.3x
P/S Ratio-27.4x
P/E RatioIs IBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBP income statement (TTM) | |
|---|---|
| Revenue | ৳119.08m |
| Cost of Revenue | ৳109.27m |
| Gross Profit | ৳9.81m |
| Other Expenses | ৳54.79m |
| Earnings | -৳44.98m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 8.23% |
| Net Profit Margin | -37.78% |
| Debt/Equity Ratio | 1.7% |
How did IBP perform over the long term?
See historical performance and comparisonDividends
0.09%
Current Dividend Yield-3%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 11:36 |
| End of Day Share Price | 2025/02/13 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indo-Bangla Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.